FIGURE 4.

The effect of Pyk2 inhibition on agonist-induced platelet aggregation and secretion. A, non-aspirin-treated and B, aspirin-treated washed human platelets were pre-treated with Pyk2 inhibitor AG17 (1 μm) at 37 °C for 5 min following stimulation with 50 nm 2-MeSADP under stirring conditions. Non-aspirin-treated and aspirin-treated (ASA) washed human platelets were preincubated with Pyk2 inhibitors (C) AG17 (1 μm) or (D) TAT-Pyk2-CT (2 μm) or TAT-GFP (control) at 37 °C for 3.5 min and stimulated with 60 μm AYPGKF. Platelet aggregation and ATP secretion were measured by aggregometry. Arrow indicates when agonist is added. Tracings are representative of experiments performed using platelets from at least three different donors.